Generic giant mylan faces anti competitive investigation in the US

Source: Ding Xiangyuan 2016-11-10 two key members of the judicial committee of the United States Senate said that Meilan did not comply with the market competition law in the process of selling its Epipen, and called for an investigation into the behavior of Meilan Grassley, chairman of the committee, and Leahy, a member of the committee, have asked the Federal Trade Commission (FTC) to launch an antitrust investigation to find out whether the company is preventing schools from buying competing allergy drugs In a letter to the federal antitrust regulator, Grassley and Leahy said the agency should investigate noble schools' contracts to restrict Epipen competitors In a letter to Ramirez, the chairwoman of the Federal Trade Commission, they said: "for a long time, making patients have access to more safe, effective and affordable drugs has been our common priority "We also have a strong belief that potential anticompetitive behavior of pharmaceutical industry participants must be investigated severely because it is related to competition and drug cost We therefore ask the FTC to investigate whether the sale of Epipen is in violation of antitrust law in any anti competitive practice conducted by mylan, and take appropriate measures to protect patients if there is any violation "For mylan Epipen, the new investigation is a complement to the ongoing investigation, which has been at the center of a public drug price scandal, with protests that the product's pricing has increased by 400% in the past six years Mylan has extended its patient access program in the U.S and is committed to the production of the emergency allergy injection generic, which is sold at less than half the current price The US company has also proposed a $465 million settlement to settle the current dispute.